FIELD: pharmaceutical chemistry. SUBSTANCE: new guanidine derivatives with formula I: (I) are provided where Y is nitrogen or group C-R1 (R1 is hydrogen, lower alkyl, hydroxyl, etc.); R2 is hydrogen, optionally substituted aryl, aryloxy group, etc.; R3 hydrogen, lower alkoxy, hydroxyl, etc.; Z nitrogen or C-R4 (R4 is hydrogen, halogen, hydroxyl, lower alkyl, etc. ); and W nitrogen or C-R12 (R12 is hydrogen) and their pharmaceutical acceptable salts. Compound of invention are useful as drugs in treatment and/or prophylactics of cardiac infarction or ischemic disease. Method of preparing these compounds is also provided. EFFECT: extended choice of cardiovascular medicines. 15 cl, 1 tbl, 34 ex
Title |
Year |
Author |
Number |
POLYPEPTIDE COMPOUNDS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF PROPHYLAXIS AND/OR THERAPEUTIC TREATMENT |
1994 |
- Khidenori Okhki
- Masaki Tomisima
- Akira Jamada
- Khisasi Takasugi
|
RU2164230C2 |
DERIVATIVES OF NAPHTHALENE, PHARMACEUTICAL COMPOSITION |
1995 |
- Taniguti Kijosi
- Nagano Masanobu
- Khattori Koudzi
- Tsubaki Kazunori
- Okitsu Osamu
- Tabuti Senitiro
|
RU2155188C2 |
1,2,3,4-TETRAHYDROPYRAZOLO-[5,1-C]-(1,2,4)-TRIAZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION INHIBITING PRODUCING AN INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, METHOD OF PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PATIENTS WITH DISEASES MEDIATED BY INTERLEUKIN AND TUMOR NECROSIS FACTOR |
1994 |
- Esio Kavai
- Khitosi Jamazaki
- Khirokazu Tanaka
- Teruo Oku
|
RU2124517C1 |
POLYPEPTIDE COMPOUND, METHOD OF ITS SYNTHESIS AND PHARMACEUTICAL COMPOSITION |
1995 |
- Khidenori Oki
- Masaki Tomisima
- Akira Jamada
- Khizasi Takazugi
|
RU2165423C2 |
INDOLIZINE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF ACTIVITY OF TESTOSTERONE-5α-REDUCTASE |
1992 |
- Satosi Okada
- Kozo Savada
- Akio Kuroda
- Sinija Vatanabe
- Khirokazu Tanaka
|
RU2120942C1 |
DERIVATIVES OF N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE AS ANTAGONISTS OF PLATELET ACTIVATION FACTOR, METHOD OF SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT |
1994 |
- Mitsuru Okhkubo
- Fumie Takakhasi
- Tosio Jamanaka
- Khiroesi Sakai
- Masajuki Kato
|
RU2161155C2 |
PYRAZOLE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS |
1993 |
- Masaaki Matsuo
- Kijosi Tsudzi
- Takasi Ogino
- Nobukijo Konisi
|
RU2128172C1 |
HETEROCYCLIC COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND INTERMEDIATE COMPOUNDS |
1994 |
- Taniguti Kiesi
- Nagano Masanobu
- Khattori Kojudzi
- Tsubaki Kazunori
- Okitsu Osamu
- Tabuti Sejitiro
|
RU2176640C2 |
PEPTIDE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF TACHYKININ EFFECT |
1993 |
- Masaaki Matsuo
- Dajdzhiro Khagivara
- Khirosi Mijake
|
RU2119922C1 |
CYCLOPEPTIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHODS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITION |
1991 |
- Tosiro Ivamoto[Jp]
- Akikhiko Fudzie[Jp]
- Kumiko Nitta[Jp]
- Jasukhisa Tsurumi[Jp]
- Nobukharu Sigematsu[Jp]
- Tijosi Kasakhara[Jp]
- Motokhiro Khino[Jp]
- Masakuni Okukhara[Jp]
- Kazuo Sakane[Jp]
- Kokhdzi Kavabata[Jp]
- Khidenori Okhki[Jp]
|
RU2108342C1 |